Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro.
Many investigations have indicated a functional role for carbonic anhydrase in the mediation of hormone-stimulated bone resorption. These studies depend heavily on the use of heterocyclic sulfonamide inhibitors of carbonic anhydrase. These drugs have effects on many tissues other than bone, and some of these effects confound the interpretation of studies of the role of carbonic acid in bone metabolism. A novel, "bone-targeted" sulfonamide has been produced to obviate these extraosseous effects. This compound (designated WP-1) is the combination of tetracycline and acetazolamide, such that the acetazolamide is not an active inhibitor. Hydrolysis of WP-1 yields an active carbonic anhydrase inhibitor. WP-1 has a marked affinity for bone mineral, allowing deposition of the drug in bone. At a concentration of 10(-5) M, WP-1 attenuates parathyroid hormone stimulated net release of calcium from neonatal rat calvaria in culture. WP-1 is the first member of a class of drugs which may prove useful as pharmacological probes in the study of bone metabolism.
D000086:Acetazolamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001862:Bone Resorption / Q000187:drug effects*; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology*; D003864:Depression, Chemical; D051381:Rats; D012886:Skull / Q000187:drug effects; D013752:Tetracycline / Q000494:pharmacology; D013754:Tetracyclines / Q000494:pharmacology*
D002257:Carbonic Anhydrase Inhibitors; D013754:Tetracyclines; C053646:WP 1; C053647:acetazolamide adipate ethyl ester; D013752:Tetracycline; D000086:Acetazolamide